Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

por Emery, Paul, Vencovský, Jiří, Sylwestrzak, Anna, Leszczyński, Piotr, Porawska, Wieslawa, Stasiuk, Barbara, Hilt, Joanna, Mosterova, Zdenka, Cheong, Soo Yeon, Ghil, Jeehoon
Publicado 2017

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

por Emery, Paul, Vencovský, Jiří, Sylwestrzak, Anna, Leszczyński, Piotr, Porawska, Wieslawa, Baranauskaite, Asta, Tseluyko, Vira, Zhdan, Vyacheslav M, Stasiuk, Barbara, Milasiene, Roma, Barrera Rodriguez, Aaron Alejandro, Cheong, Soo Yeon, Ghil, Jeehoon
Publicado 2017

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

por Emery, Paul, Vencovský, Jiří, Sylwestrzak, Anna, Leszczyński, Piotr, Porawska, Wieslawa, Baranauskaite, Asta, Tseluyko, Vira, Zhdan, Vyacheslav M., Stasiuk, Barbara, Milasiene, Roma, Barrera Rodriguez, Aaron Alejandro, Cheong, Soo Yeon, Ghil, Jeehoon
Publicado 2017